24 results
Thumbnail

D1.422 - A service review of the complex COVID-19 vaccination service

Thumbnail

D1.425 - Familial Cold Autoinflammatory Syndrome Post COVID-19 Vaccine: A Case Report

Thumbnail

D1.423 - Listening to Urticaria Patients Through Social Media: Analyzing the Impact of the COVID-19 Pandemic

Thumbnail

D1.424 - Clinical-epidemiological profile of patients with Post-Covid syndrome followed at a medical school outpatient clinic

Thumbnail

D1.426 - Cellular immunity profile in patients with urolithiasis in the presence of post-Covid syndrome

Thumbnail

D3.34 - Cephalosporine drug provocation in a population of children with confirmed serum sickness-like reaction to amoxicillin

Thumbnail

D3.35 - Severe atopic dermatitis poorly controlled, or something else?

Thumbnail

D3.36 - Contact allergy to sodium metabisulfite in Singapore: A single-center retrospective study of patch test data from 2004 to 2021

Thumbnail

D3.37 - Beware of the Rare: AGEP

Thumbnail

D3.39 - Autoimmune Progesterone Dermatitis Case Report

Thumbnail

D3.42 - Symmetrical drug-related intertriginous and flexural exanthema related to symptomatic slow-acting drug for osteoarthritis (SYSADOA) – a case report

Thumbnail

D3.44 - The Role of Medical History and Diagnostic Testing in Identifying Post-Surgical Allergic Reactions

Thumbnail

D3.45 - Perioperative Immediate Hypersensitivity Reactions: First Chilean Cohort Study 2020-2024 Clinical Hospital University of Chile

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series